Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20163
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKaravasilis, V.en
dc.contributor.authorMalamou-Mitsi, V.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorTsanou, E.en
dc.contributor.authorKitsou, E.en
dc.contributor.authorKalofonos, H.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorFotsis, T.en
dc.contributor.authorPavlidis, N.en
dc.date.accessioned2015-11-24T19:05:14Z-
dc.date.available2015-11-24T19:05:14Z-
dc.identifier.issn0008-543X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20163-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectCarcinoma/*enzymology/*secondaryen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectMaleen
dc.subjectMatrix Metalloproteinases/*metabolismen
dc.subjectMiddle Ageden
dc.subjectNeoplasms, Unknown Primary/*enzymologyen
dc.subjectPrognosisen
dc.subjectTissue Inhibitor of Metalloproteinases/metabolismen
dc.subjectTumor Markers, Biological/analysisen
dc.titleMatrix metalloproteinases in carcinoma of unknown primaryen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1002/cncr.21454-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16220559-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1002/cncr.21454/asset/21454_ftp.pdf?v=1&t=h0p0dpyu&s=8cf753d10afbaa0eec1fb8ed90d174d4cbd7fb6a-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2005-
heal.abstractBACKGROUND: The purpose was to study proteolysis-related molecules, matrix metalloproteinase-2 (MMP-2) and MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1), in carcinoma of unknown primary (CUP). METHODS: Paraffin-embedded tumor material from 75 patients diagnosed with CUP was used. Tumor histologies were adenocarcinoma (77%), undifferentiated carcinoma (19%), and squamous cell carcinoma (4%) and patients were categorized into favorable (62%) and unfavorable (38%) subsets. The tissue expression of MMP-2, MMP-9, and TIMP-1 was assessed by use of specific monoclonal antibodies and evaluated by means of a visual staining score. The expression of molecules studied was analyzed against clinicopathological data. RESULTS: MMP-2 was found expressed in 69% (strong expression in 49%), MMP-9 in 49% (strong in 36%), and TIMP-1 in 79% (strong in 44%) of studied cases. The expression of MMP-2 correlated positively with MMP-9. TIMP-1 was significantly higher in unfavorable compared with favorable tumors and was associated with a shorter survival of patients (7.5 vs. 12 mos). No other associations were detected. CONCLUSIONS: MMP-2, MMP-9, and TIMP-1 are widely expressed in CUP, suggesting an essential role of proteolysis in these tumors. TIMP-1 may be considered a possible marker of poor prognosis in CUP patients.en
heal.journalNameCanceren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Karavasilis-2005-Matrix metalloprotei.pdf252.2 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons